As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Celldex Therapeutics Inc. The largest reported stake is Wellington Management Group LLP's, at 12.2%. 19 filings are on record since July 10, 2025 (Schedule 13G/A, February 10, 2026).
Sell to companies like Celldex Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 8,396,651 · Shared voting: 0 · Sole dispositive: 8,411,905 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: Kynam Capital Management, LP · Sole voting: 0 · Shared voting: 5,322,908 · Sole dispositive: 0 · Shared dispositive: 5,322,908 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 4,683,226 · Shared voting: 0 · Sole dispositive: 4,686,187 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Holder: Bellevue Group AG · Percent: 1.5% · SCHEDULE 13G/A
- · Holder: Kynam Capital Management, LP · Percent: 8.77% · SCHEDULE 13G/A
Celldex Therapeutics Inc has 19 Schedule 13D or 13G filings on record since 2025-07-10. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Wellington Management Group LLP | 12.2% | 8,079,608 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| Fmr LLC | 10.7% | 8,411,905 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| Kynam Capital Management, LP | 6.78% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| T. Rowe Price Associates, Inc. | 6% | 4,686,187 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Vanguard Capital Management | 5.17% | 3,446,795 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Commodore Capital LP | 4.6% | 3,028,335 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| State Street Corporation | 4.2% | 2,804,168 | SCHEDULE 13G, 2026-05-12 | 2026-03-31 |
| Point72 Asset Management, L.P. | 2.6% | 1,758,357 | SCHEDULE 13G/A, 2026-03-10 | 2025-12-31 |
| Eventide Asset Management, LLC | 2% | 1,356,186 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Bellevue Group AG | 1.5% | 1,200,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Celldex Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Celldex Therapeutics Inc and the records around it.
Celldex Therapeutics Inc elsewhere on the record
Companies that share a holder
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Viridian Therapeutics, Inc. (May 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026), Viridian Therapeutics, Inc. (Aug 2026)
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026)
Watch Celldex Therapeutics Inc
Get an email when Celldex Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Celldex Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Celldex Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Celldex Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 8,396,651 | 0 | 8,411,905 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Abigail P. Johnson | 0 | 0 | 8,411,905 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Kynam Capital Management, LP | 0 | 5,322,908 | 0 | 5,322,908 | SCHEDULE 13G/A, 2026-08-14 |
| Kynam Capital Management GP, LLC | 0 | 5,322,908 | 0 | 5,322,908 | SCHEDULE 13G/A, 2026-08-14 |
| Yue Tang | 0 | 5,322,908 | 0 | 5,322,908 | SCHEDULE 13G/A, 2026-08-14 |
| T. Rowe Price Associates, Inc. | 4,683,226 | 0 | 4,686,187 | 0 | SCHEDULE 13G, 2026-08-14 |
The latest filing identifies Celldex Therapeutics Inc by CUSIP 15117B202 and gives its principal executive office as 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ 08827 (SCHEDULE 13G/A, 2026-10-07).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-10 | Point72 Asset Management, L.P. | 6.7% | SCHEDULE 13G |
| 2025-08-12 | Wellington Management Group LLP | 7.9% | SCHEDULE 13G/A |
| 2025-08-14 | Eventide Asset Management, LLC | 2% | SCHEDULE 13G/A |
| 2025-11-07 | Wellington Management Group LLP | 11.1% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 3.6% | SCHEDULE 13G/A |
| 2025-11-14 | Bellevue Group AG | 5.4% | SCHEDULE 13G |
| 2025-11-14 | Commodore Capital LP | 4.6% | SCHEDULE 13G/A |
| 2026-02-09 | State Street Corporation | 5.1% | SCHEDULE 13G |
| 2026-02-10 | Wellington Management Group LLP | 12.2% | SCHEDULE 13G/A |
| 2026-03-10 | Point72 Asset Management, L.P. | 2.6% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Capital Management | 5.17% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 5.6% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 4.2% | SCHEDULE 13G |
| 2026-05-15 | Bellevue Group AG | 1.5% | SCHEDULE 13G/A |
| 2026-05-15 | Kynam Capital Management, LP | 8.77% | SCHEDULE 13G/A |
| 2026-08-14 | T. Rowe Price Associates, Inc. | 6% | SCHEDULE 13G |
| 2026-08-14 | Kynam Capital Management, LP | 6.78% | SCHEDULE 13G/A |
| 2026-10-07 | Fmr LLC | 10.7% | SCHEDULE 13G/A |
Questions about who owns Celldex Therapeutics Inc
Who owns Celldex Therapeutics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Celldex Therapeutics Inc: Wellington Management Group LLP (12.2%, Schedule 13G/A, filed 2026-02-10), Fmr LLC (10.7%, Schedule 13G/A, filed 2026-10-07), Kynam Capital Management, LP (6.78%, Schedule 13G/A, filed 2026-08-14), T. Rowe Price Associates, Inc. (6%, Schedule 13G, filed 2026-08-14) and Vanguard Capital Management (5.17%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Celldex Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Celldex Therapeutics Inc on this page are Wellington Management Group LLP (12.2%), Fmr LLC (10.7%) and Kynam Capital Management, LP (6.78%).
When did Wellington Management Group LLP buy into Celldex Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Wellington Management Group LLP on this page is the Schedule 13G/A, filed 2025-08-12, reporting 7.9%; its latest, Schedule 13G/A filed 2026-02-10, reports 12.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Celldex Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.